m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00403)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
SOX10
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Fat mass and obesity-associated protein (FTO) [ERASER]
Representative RNA-seq result indicating the expression of this target gene regulated by FTO | ||
Cell Line | Cerebral cortex | Mus musculus |
Treatment: METTL3 (f/f, Emx1-cre) cerebral cortex
Control: Wild type cerebral cortex
|
GSE154992 | |
Regulation |
![]() ![]() |
logFC: -8.13E-01 p-value: 2.61E-03 |
More Results | Click to View More RNA-seq Results |
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and Transcription factor SOX-10 (SOX10), leading to increased RNA decay through the m6A reader YTHDF2. | |||
Target Regulation | Up regulation | |||
Responsed Disease | Melanoma | ICD-11: 2C30 | ||
Responsed Drug | PMID31239444-anti-PD1 antibody | Investigative | ||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | mRNA decay | |||
In-vitro Model | B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 |
CHL-1 | Melanoma | Homo sapiens | CVCL_1122 | |
624-mel | Melanoma | Homo sapiens | CVCL_8054 | |
NHEM (Normal Human Epidermal Melanocytes) | ||||
SK-MEL-30 | Cutaneous melanoma | Homo sapiens | CVCL_0039 | |
WM115 | Melanoma | Homo sapiens | CVCL_0040 | |
WM35 | Melanoma | Homo sapiens | CVCL_0580 | |
WM3670 | Melanoma | Homo sapiens | CVCL_6799 | |
WM793 | Melanoma | Homo sapiens | CVCL_8787 | |
In-vivo Model | When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation. | |||
YTH domain-containing family protein 2 (YTHDF2) [READER]
In total 1 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and Transcription factor SOX-10 (SOX10), leading to increased RNA decay through the m6A reader YTHDF2. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Melanoma | ICD-11: 2C30 | ||
Responsed Drug | PMID31239444-anti-PD1 antibody | Investigative | ||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | mRNA decay | |||
In-vitro Model | B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 |
CHL-1 | Melanoma | Homo sapiens | CVCL_1122 | |
624-mel | Melanoma | Homo sapiens | CVCL_8054 | |
NHEM (Normal Human Epidermal Melanocytes) | ||||
SK-MEL-30 | Cutaneous melanoma | Homo sapiens | CVCL_0039 | |
WM115 | Melanoma | Homo sapiens | CVCL_0040 | |
WM35 | Melanoma | Homo sapiens | CVCL_0580 | |
WM3670 | Melanoma | Homo sapiens | CVCL_6799 | |
WM793 | Melanoma | Homo sapiens | CVCL_8787 | |
In-vivo Model | When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation. | |||
Melanoma [ICD-11: 2C30]
In total 2 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and Transcription factor SOX-10 (SOX10), leading to increased RNA decay through the m6A reader YTHDF2. | |||
Responsed Disease | Melanoma [ICD-11: 2C30] | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Responsed Drug | PMID31239444-anti-PD1 antibody | Investigative | ||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | mRNA decay | |||
In-vitro Model | B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 |
CHL-1 | Melanoma | Homo sapiens | CVCL_1122 | |
624-mel | Melanoma | Homo sapiens | CVCL_8054 | |
NHEM (Normal Human Epidermal Melanocytes) | ||||
SK-MEL-30 | Cutaneous melanoma | Homo sapiens | CVCL_0039 | |
WM115 | Melanoma | Homo sapiens | CVCL_0040 | |
WM35 | Melanoma | Homo sapiens | CVCL_0580 | |
WM3670 | Melanoma | Homo sapiens | CVCL_6799 | |
WM793 | Melanoma | Homo sapiens | CVCL_8787 | |
In-vivo Model | When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation. | |||
Experiment 2 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and Transcription factor SOX-10 (SOX10), leading to increased RNA decay through the m6A reader YTHDF2. | |||
Responsed Disease | Melanoma [ICD-11: 2C30] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Drug | PMID31239444-anti-PD1 antibody | Investigative | ||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | mRNA decay | |||
In-vitro Model | B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 |
CHL-1 | Melanoma | Homo sapiens | CVCL_1122 | |
624-mel | Melanoma | Homo sapiens | CVCL_8054 | |
NHEM (Normal Human Epidermal Melanocytes) | ||||
SK-MEL-30 | Cutaneous melanoma | Homo sapiens | CVCL_0039 | |
WM115 | Melanoma | Homo sapiens | CVCL_0040 | |
WM35 | Melanoma | Homo sapiens | CVCL_0580 | |
WM3670 | Melanoma | Homo sapiens | CVCL_6799 | |
WM793 | Melanoma | Homo sapiens | CVCL_8787 | |
In-vivo Model | When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation. | |||
PMID31239444-anti-PD1 antibody
[Investigative]
In total 2 item(s) under this drug | ||||
Experiment 1 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and Transcription factor SOX-10 (SOX10), leading to increased RNA decay through the m6A reader YTHDF2. | |||
Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
Target Regulation | Up regulation | |||
Responsed Disease | Melanoma | ICD-11: 2C30 | ||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | mRNA decay | |||
In-vitro Model | B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 |
CHL-1 | Melanoma | Homo sapiens | CVCL_1122 | |
624-mel | Melanoma | Homo sapiens | CVCL_8054 | |
NHEM (Normal Human Epidermal Melanocytes) | ||||
SK-MEL-30 | Cutaneous melanoma | Homo sapiens | CVCL_0039 | |
WM115 | Melanoma | Homo sapiens | CVCL_0040 | |
WM35 | Melanoma | Homo sapiens | CVCL_0580 | |
WM3670 | Melanoma | Homo sapiens | CVCL_6799 | |
WM793 | Melanoma | Homo sapiens | CVCL_8787 | |
In-vivo Model | When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation. | |||
Experiment 2 Reporting the m6A-centered Drug Response | [1] | |||
Response Summary | These findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade reduces the resistance to immunotherapy in melanoma. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and Transcription factor SOX-10 (SOX10), leading to increased RNA decay through the m6A reader YTHDF2. | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Responsed Disease | Melanoma | ICD-11: 2C30 | ||
Pathway Response | PD-L1 expression and PD-1 checkpoint pathway in cancer | hsa05235 | ||
Cell Process | mRNA decay | |||
In-vitro Model | B16-F10 | Mouse melanoma | Mus musculus | CVCL_0159 |
CHL-1 | Melanoma | Homo sapiens | CVCL_1122 | |
624-mel | Melanoma | Homo sapiens | CVCL_8054 | |
NHEM (Normal Human Epidermal Melanocytes) | ||||
SK-MEL-30 | Cutaneous melanoma | Homo sapiens | CVCL_0039 | |
WM115 | Melanoma | Homo sapiens | CVCL_0040 | |
WM35 | Melanoma | Homo sapiens | CVCL_0580 | |
WM3670 | Melanoma | Homo sapiens | CVCL_6799 | |
WM793 | Melanoma | Homo sapiens | CVCL_8787 | |
In-vivo Model | When the tumors reached a volume of 80-100 mm3, mice were treated with anti-PD-1 or isotype control antibody (200 ug/mouse) by i.p. injection, every other day for three times. For IFNγ blockade treatment, C57BL/6 mice were treated with anti-IFNγ antibody or isotype control IgG (250 ug/mouse) every other day after tumor cell inoculation. | |||